VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | ADAURA: the benefit of adjuvant osimertinib

Tony Greco, MD, Tennessee Oncology, Nashville, TN, shares his highlights from ASCO 2020, in particular the ADAURA study (NCT02511106) in which patients with stage IB–IIIA EGFR mutation-positive non-small cell lung carcinoma patients were treated with osimertinib as adjuvant therapy after complete tumor resection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter